# OnCo record ductal-carcinoma-in-situ (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/ductal-carcinoma-in-situ/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "ductal-carcinoma-in-situ" ;
  schema:name "Ductal carcinoma in situ (DCIS)"@en ;
  schema:alternateName "DCIS"@en, "Stage 0 breast cancer"@en, "Pre-invasive breast cancer"@en, "Intraductal carcinoma"@en ;
  schema:description "DCIS is abnormal cells confined to the milk ducts of the breast; it is not yet invasive cancer and cannot spread, but some would become invasive if left. Lumpectomy with radiotherapy, or mastectomy, halves local recurrence, so the live question is which low-risk DCIS can safely be watched: the COMET trial (2024) found active monitoring no worse at two years."@en ;
  schema:url <https://onco.cc/cancers/ductal-carcinoma-in-situ/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ductal_carcinoma_in_situ> ;
  schema:citation <https://www.cancer.gov/types/breast/breast-cancer-types/dcis>, <https://doi.org/10.1001/jama.2024.26698>, <https://doi.org/10.1200/JCO.2016.68.3573>, <https://clinicaltrials.gov/study/NCT02492607> ;
  onco:tag "nci-coverage", "breast", "overdiagnosis" ;
  onco:related <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/male-breast-cancer/>, <https://onco.cc/cancers/paget-disease-of-the-nipple/>, <https://onco.cc/cancers/phyllodes-tumour/> ;
  onco:technologies <https://onco.cc/technologies/mammography/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/radiology-ai-screening/>, <https://onco.cc/technologies/mri/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/oncotype-dx/>, <https://onco.cc/drugs/mammaprint/>, <https://onco.cc/drugs/anastrozole/> ;
  onco:pathways <https://onco.cc/pathways/er-signaling/> ;
  onco:terms <https://onco.cc/terms/dcis/>, <https://onco.cc/terms/carcinoma-in-situ/>, <https://onco.cc/terms/lumpectomy/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/terms/in-situ/> ;
  onco:trials <https://onco.cc/trials/nsabp-b39/>, <https://onco.cc/trials/comet-dcis/>, <https://onco.cc/trials/tam-01/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-overdiagnosis/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-morrow-j-clin-oncol/> ;
  onco:pipeline <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/oncotype-dx/>, <https://onco.cc/drugs/tamoxifen/> ;
  onco:standardOfCare <https://onco.cc/terms/lumpectomy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/oncotype-dx/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/terms/dcis/>, <https://onco.cc/bottlenecks/b-overdiagnosis/> .